The U.S. Department of Defense has released detailed instructions for a new mandatory testosterone deficiency screening policy targeting active-duty and reserve service members aged 30 and above. This directive, announced by U.S. Secretary of War Pete Hegseth in July, aims to enhance military readiness by identifying and addressing hormonal and energy-related issues through standardized screening and treatment procedures for both male and female personnel.
The policy, effective immediately, requires men aged 30 and older to undergo compulsory testosterone blood tests, with younger men being tested upon request or if warning signs are identified by healthcare providers. While routine testosterone testing is not mandatory for women, screening for symptoms such as fatigue and menstrual irregularities associated with hormonal imbalances and energy deficiencies is recommended.
Furthermore, the guidelines specify circumstances under which off-label testosterone prescription is appropriate for women, particularly for postmenopausal individuals experiencing significantly reduced sexual desire. Despite these measures, concerns have been raised by medical professionals regarding the potential risks of unnecessary or harmful treatment resulting from widespread testosterone testing. Critics argue that there is limited evidence supporting the notion that universal screening for low testosterone levels would enhance U.S. combat readiness among military personnel.